康泰生物：2025年上半年净利润同比下降77.30%

Core Viewpoint - The company reported a revenue of 1.392 billion yuan for the first half of 2025, reflecting a year-on-year growth of 15.81%. However, the net profit attributable to shareholders decreased significantly by 77.30% to 37.5327 million yuan, with basic earnings per share dropping by 80.00% to 0.03 yuan per share. The company has decided not to distribute cash dividends, issue bonus shares, or increase capital from reserves [1]. Financial Performance - Revenue for the first half of 2025 reached 1.392 billion yuan, marking a 15.81% increase compared to the previous year [1]. - Net profit attributable to shareholders was 37.5327 million yuan, which represents a decline of 77.30% year-on-year [1]. - Basic earnings per share stood at 0.03 yuan, down 80.00% from the same period last year [1]. Dividend Policy - The company announced that it will not distribute cash dividends, issue bonus shares, or utilize reserves for capital increase [1].